Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

Summary

The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis. The secondary objectives are to determine whether ACP-103 will ameliorate psychosis in patients with Parkinson's disease and whether ACP-103 is safe in Parkinson's disease patients taking multiple anti-parkinsonian medications.

Timeline

Start

2004-03

Primary completion

—

Completion

2005-12

Drugs

Indications